Glaxosmithkline Says Roche's Herceptin Infringes Patents

Drugmaker Glaxosmithkline sued Swiss rival Roche on Tuesday for infringing a patent when it produces its cancer drug Herceptin, according to court documents filed on Monday.

Glaxo said the patents were issued in 2008 and 2010 and cover antibody purification. Roche and its U.S. business Genentech infringe the patent by "making and/or having made therapeutic antibody products, including without limitation Herceptin," the complaint said.

Glaxo is demanding damages to compensate for violations of its patent.

Genentech declined to comment except to say that it was aware of the lawsuit and that a second lawsuit had been filed in the Northern District of California. The California lawsuit was brought by Genentech against Glaxo, according to Caroline Pecquet, a Genentech spokeswoman.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.